MIRA Pharmaceuticals (MIRA) Stock Analysis

What MIRA Pharmaceuticals does

MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

Key metrics

ETFs linked to MIRA

Broad-market and Healthcare sector ETFs an investor holding MIRA Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MIRA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for MIRA Pharmaceuticals?

MIRA Pharmaceuticals trades under the ticker MIRA on NASDAQ.

Which exchange is MIRA listed on?

MIRA is listed on NASDAQ.

What sector does MIRA Pharmaceuticals operate in?

MIRA Pharmaceuticals is classified in the Healthcare sector (Drug Manufacturers - General industry).

How can PortView help analyze MIRA in a portfolio?

PortView shows MIRA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.